- Home
- MRCC vs ALEC Comparison
MRCC vs ALEC Comparison
Compare MRCC & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- ALEC
- Stock Information
- Founded
- MRCC 2011
- ALEC 2013
- Country
- MRCC United States
- ALEC United States
- Employees
- MRCC N/A
- ALEC N/A
- Industry
- MRCC Investment Managers
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRCC Finance
- ALEC Health Care
- Exchange
- MRCC Nasdaq
- ALEC Nasdaq
- Market Cap
- MRCC 151.7M
- ALEC 124.0M
- IPO Year
- MRCC 2012
- ALEC 2019
- Fundamental
- Price
- MRCC $7.00
- ALEC $3.07
- Analyst Decision
- MRCC Hold
- ALEC Buy
- Analyst Count
- MRCC 1
- ALEC 7
- Target Price
- MRCC $8.00
- ALEC $4.50
- AVG Volume (30 Days)
- MRCC 98.5K
- ALEC 1.3M
- Earning Date
- MRCC 11-11-2025
- ALEC 11-05-2025
- Dividend Yield
- MRCC 14.24%
- ALEC N/A
- EPS Growth
- MRCC N/A
- ALEC N/A
- EPS
- MRCC 0.09
- ALEC N/A
- Revenue
- MRCC $51,229,000.00
- ALEC $81,130,000.00
- Revenue This Year
- MRCC N/A
- ALEC N/A
- Revenue Next Year
- MRCC N/A
- ALEC $290.50
- P/E Ratio
- MRCC $79.46
- ALEC N/A
- Revenue Growth
- MRCC N/A
- ALEC 46.77
- 52 Week Low
- MRCC $5.96
- ALEC $0.87
- 52 Week High
- MRCC $8.85
- ALEC $6.14
- Technical
- Relative Strength Index (RSI)
- MRCC 40.33
- ALEC 54.68
- Support Level
- MRCC $6.90
- ALEC $2.83
- Resistance Level
- MRCC $7.13
- ALEC $3.33
- Average True Range (ATR)
- MRCC 0.17
- ALEC 0.21
- MACD
- MRCC -0.05
- ALEC -0.03
- Stochastic Oscillator
- MRCC 12.64
- ALEC 43.00
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.